The concern of generic competition has long loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the future of similar medicinal ventures. While first periods saw impressive gains, the intellectual property end has created the way for less expensive substitutes, potentially diminishing profitability and posing a signi